Category: Oncology
-
Molecular Partners unveils first human data for cancer radiotherapy
The company reveals first human data for its DLL3-targeting radiopharmaceutical MP0712, showing precise tumor targeting and limited healthy organ exposure.
-
Intensity bolsters survival data for its intratumoral cancer therapy
The company’s stock shot up by approximately 394%, driven by the cancer therapy’s strong overall survival and disease control results.
-
Bayer scores UK NICE nod for Nubeqa in prostate cancer
NICE approves Bayer’s Nubeqa (darolutamide) plus androgen deprivation therapy (ADT) for treating men with hormone-sensitive metastatic prostate cancer.
-
Boston Scientific study finds cryoablation more cost-effective than surgery
A Danish study finds cryoablation equally effective as robotic surgery for kidney cancer, but at 32% lower cost in patients with kidney cancer.
-
Telix starts clinical trial for pain therapy for metastatic bone cancer
Telix Pharmaceuticals doses first patient in its SOLACE trial, testing a non-opioid radiopharmaceutical for advanced cancer pain.
-
ESMO 2025: Promising Phase II data for Sanofi’s alpha therapy
Investigational targeted alpha therapy AlphaMedix shows clinical activity in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
-
Enterome’s lymphoma drug wins FDA fast track designation
The company is exploring EO2463’s efficacy in relapsed or refractory settings in a Phase I/II trial, with plans to start Phase III registrational trial in a “watch-and-wait” iNHL patient population
-
Resitu wins FDA clearance for breast biopsy device
Swedish MedTech firm has received US FDA 510(k) clearance for a handheld, single-use device designed for minimally invasive biopsy.
-
Israeli biotech institute launches with $120m in funds
Bar-Ilan University and Sheba Medical Center launch a $120 million research hub focusing on cancer research, 3D printing, AI, robotics, and genetic engineering.
-
RadioMedix and Vect-Horus launch exploratory cancer radiopharmaceutical study
The first patient has been dosed in an exploratory Investigational New Drug (IND) study targeting glioblastoma multiforme and pancreatic cancer.
-
Imagene AI and Sheba launch alliance to advance precision oncology
Partnership combines real-world data and AI to accelerate biomarker discovery and personalized cancer care.
-
Telix and US FDA set path for glioma imaging agent resubmission
Telix secures FDA resubmission plan for TLX101-CDx after prior setbacks and additional data requests, with NDA filing expected in Q4.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.